Print（PDF/136KB） Jul. 29, 2022 Finances

Notice Concerning Finance Income

Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, Prime Market of TSE) announced today that it recorded finance income for the first quarter of the fiscal year ending March 31, 2023 (from April 1, 2022 to June 30, 2022) as follows.

1. Details of Finance Income
The Company recorded a foreign exchange gain of 31,907 million yen under finance income for the first quarter of the fiscal year ending March 31, 2023 due to recent fluctuations in foreign exchange rates. This was mainly due to the valuation of assets denominated in foreign currencies.

2. Future Outlook
Regarding the impact of the above finance income on the results of the Company operations, please refer to the "Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2023 [IFRS]" announced today. Since the amount will fluctuate depending on the future foreign exchange rates, the Company has not revised the financial forecasts at this time.